The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 24, 2021

Filed:

Oct. 22, 2018
Applicant:

Curelab Oncology, Inc., Dedham, MA (US);

Inventors:

Alexander Shneider, Dedham, MA (US);

Franco Venanzi, Camerino, IT;

Dimitrios Agas, Camerino, IT;

Antonio Concetti, Falerone, IT;

Maria Giovanna Sabbieti, Camerino, IT;

Vladimir Gabai, Brighton, MA (US);

Michael Sherman, Newton, MA (US);

Victor Shifrin, Newton, MA (US);

Assignee:

CureLab Oncology, Inc., Dedham, MA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 14/545 (2006.01); A61K 45/06 (2006.01); A61K 38/17 (2006.01); C07K 14/47 (2006.01); A61K 39/00 (2006.01); A61P 25/28 (2006.01); A61P 37/06 (2006.01); A61P 29/00 (2006.01); A61K 31/436 (2006.01); A61K 31/519 (2006.01); A61K 31/573 (2006.01); C07K 14/52 (2006.01); C07K 14/525 (2006.01); C07K 14/54 (2006.01); C07K 16/24 (2006.01); C12N 15/62 (2006.01);
U.S. Cl.
CPC ...
C07K 14/545 (2013.01); A61K 31/436 (2013.01); A61K 31/519 (2013.01); A61K 31/573 (2013.01); A61K 38/1709 (2013.01); A61K 39/0005 (2013.01); A61K 39/0008 (2013.01); A61K 45/06 (2013.01); A61P 25/28 (2018.01); A61P 29/00 (2018.01); A61P 37/06 (2018.01); C07K 14/47 (2013.01); C07K 14/523 (2013.01); C07K 14/525 (2013.01); C07K 14/5412 (2013.01); C07K 16/245 (2013.01); C07K 16/248 (2013.01); C12N 15/62 (2013.01); A61K 2039/53 (2013.01); A61K 2039/55566 (2013.01);
Abstract

Provided herein are novel p62 compositions for the modulation of expression of a proinflammatory cytokines, osteogenic transcription factors, a bone resorptive factors and endogenous p62. Consequently, such p62 compositions are useful for prophylaxis and treatment of inflammatory diseases and related methods. In certain embodiments the inflammatory diseases are not cancer-related. In various embodiments, the inflammatory diseases include, but are not limited to osteoporosis, obesity, metabolic syndrome, type 2 diabetes, fat liver, inflammatory bowel disease, chronic pancreatitis, asthma, chronic obstructive pulmonary disease (COPD), rheumatoid arthritis (RA), osteoarthritis, multiple sclerosis (MS), psoriasis, congestive heart failure (CHF), atherosclerosis, neurodegenerative diseases (ALS, Parkinson, Alzheimer's, Huntington disease), depression, schizophrenia, gout, asbestosis and silicosis.


Find Patent Forward Citations

Loading…